Note: Ingredients listed on restricted chemical lists
EC/CAS
215-691-6/1344-28-1
Name of the chemical
aluminium oxide
Concentration
Proprietary
EC/CAS
8004-92-0
Name of the chemical
1H-Indene-1,3(2H)-dione, 2-(2-quinolinyl)-, sulfonated, sodium salts (CI 47005) (35), (36)
Concentration
Proprietary
EC/CAS
9004-65-3
Name of the chemical
methylhydroxypropylcellulose
Concentration
Proprietary
EC/CAS
215-570-8/1332-37-2
Name of the chemical
iron oxide
Concentration
Proprietary
EC/CAS
232-674-9/9004-34-6
Name of the chemical
cellulose
Concentration
Proprietary
EC/CAS
500-038-2/25322-68-3
Name of the chemical
polyethyleneglycol
Concentration
038-2
EC/CAS
232-679-6/9005-25-8
Name of the chemical
Starch
Concentration
Proprietary
EC/CAS
13463-67-7
Name of the chemical
Reaction mass of titanium dioxide and silver chloride
Concentration
236-675-
EC/CAS
200-559-2
Name of the chemical
Lactose C12H22O11
Concentration
Proprietary
EC/CAS
209-150-3
Name of the chemical
Aluminium, zinc, magnesium and calcium stearates
Concentration
Proprietary
General Information
Revision date
2014-03-11
Product name
RISPERIDONE TABLET, FILM-COATED
Chemical name
For Active Ingredient
1.2.2. Uses advised against
Other than Relevant Use
Manufacturer Name
TEVA
Emergency telephone
1-800/424-9300, 01-703-527-3887
Icons in SDS
Company Information
company name
TEVA
e-mail address of the competent person responsible for the Safety Data Sheet
TevaSDSRequest@tevapharm.com
Section 2
SECTION 2: Hazards identification
Product definition
This product is supplied as odorless, round, dark yellow (0.25 mg), red-brown (0.5 mg), white to off-white (1 mg), orange (2 mg), yellow (3 mg) or green (4 mg) tablets. Health Hazards: In the workplace, exposure via inhalation and skin contact may cause irritation. Dusts from tablets can cause mechanical irritation to the eyes. Accidental ingestion may be harmful. In therapeutic use, the most common adverse effects reported include somnolence, increased appetite, fatigue, insomnia, sedation, parkinsonism, unpleasant sensations of inner restlessness, vomiting, cough, constipation, nasopharyngitis, drooling, runny nose, dry mouth, abdominal pain upper, dizziness, nausea, anxiety, headache, nasal congestion, inflammation of nasal mucous membranes, tremor, and rash. Therapeutic use may cause adverse effects on the metabolic, central nervous and cardiovascular systems, and can cause blood disorders, which can be severe or fatal. In susceptible persons, therapeutic use may cause a severe reaction (Neuroleptic Malignant Syndrome [NMS]) accompanied with fever and body rigidity, renal failure and other serious symptoms, which can also be fatal. In certain individuals, long-term use may cause a condition that causes involuntary movements and can be permanent. Severe anaphylactic reactions have been reported. Some human evidence indicates possible harm to fetus during pregnancy. Limited evidence of adverse effect on fertility, based on animal information. Breast-feeding during therapeutic use may harm to infants. These effects may be possible as a result of workplace exposure. See Section 11 (Toxicological Information) for information on other potential health hazards known from therapeutic use. Flammability Hazards: This product requires substantial pre-heating before ignition occurs. When involved in a fire, this product may decompose and produce irritating vapors and toxic compounds (including aluminum, carbon, iron, magnesium, titanium, silicon, sodium and nitrogen oxides and hydrogen fluoride). Reactivity Hazards This product is not reactive.
Environmental hazards
The active ingredient is toxic to aquatic organisms and can cause long term damage in an aquatic environment. Release to the environment may have adverse effect. Emergency Recommendations: Emergency responders must wear personal protective equipment suitable for the situation to which they are responding.